Yasmin is not recommended for use within NHS Scotland.
REASONS FOR ADVICE
There is no evidence that Yasmin, a new combined oral contraceptive (COC) pill has effects superior to other standard strength COCs on acne, pre-menstrual symptoms or well-being.
A statistically significant favourable weight change of 0.3 – 0.7 kg compared to a standard strength COC (over a period of 26 cycles) comes at a substantially increased cost. There is no evidence that patients who discontinue other COCs because of weight gain tolerate Yasmin any better.
Yasmin is substantially more expensive than competitor products and provides little additional benefits for this additional cost.
Download detailed advice19KB (PDF)
- Medicine name:
- Drospirenone ethinylestradiol (Yasmin®)
- SMC ID:
- Oral contraception
- Pharmaceutical company
- Schering Health Care Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Not recommended
- Date advice published
- 07 March 2003